Cepheid, a California-based molecular diagnostics company, and the Foundation for Innovative New Diagnostics (FIND) announced a new collaboration to accelerate the development of a rapid HIV viral load test. This viral load test will run on the platform of Cepheid’s GeneXpert, the ground-breaking rapid test to diagnose drug-susceptible and drug-resistant tuberculosis. Given the high rates of TB/HIV co-infection, especially in southern Africa, a diagnostic with both these capabilities could be incredibly beneficial in diagnosing and managing these two deadly infectious diseases. To read the full press announcement, click here.
UNAIDS HIV Gap Report highlights inequity of gains, says inclusion and ambitious acceleration could end epidemic by 2030
Of 35 million people living with HIV, 19 million do not know it. While new infections dropped by 13 percent in last three years, more than […]
PaMZ TB drug regimen: Cheaper, simpler, safer and with effectiveness “significantly greater” than standard regimen, researchers say
An analysis of eight-week data from a clinical trial of a tuberculosis treatment regimen shows the promise of curing the disease in a shorter period of […]
Along with maintaining funding for fighting global tuberculosis, the United States government must better coordinate with the most affected countries on TB research and development, said […]
WASHINGTON, DC — Health leaders who gathered Wednesday at the White House to commemorate World Hepatitis Day agreed that recognition of the needless toll and continuing […]